Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study
Authors
Keywords
-
Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 15, Issue 11, Pages 2125-2137
Publisher
Wiley
Online
2017-08-29
DOI
10.1111/jth.13815
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options
- (2016) Jack E. Ansell American Journal of Cardiovascular Drugs
- Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers
- (2016) S Nagalla et al. CTS-Clinical and Translational Science
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
- (2016) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emergency neurosurgical care in patients treated with apixaban: report of 2 cases
- (2015) Christopher Beynon et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
- (2015) Hein Heidbuchel et al. EUROPACE
- Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban
- (2015) R. Durie et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage
- (2015) E. Herzog et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- In vivoincrease in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers
- (2015) Y. W. Cheung et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial
- (2015) Joshua N Goldstein et al. LANCET
- Idarucizumab for Dabigatran Reversal
- (2015) Charles V. Pollack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
- (2015) Deborah M. Siegal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation
- (2015) Wilson W. Lam et al. TEXAS HEART INSTITUTE JOURNAL
- Addition of prothrombin to plasma can result in a paradoxical increase in activated partial thromboplastin time
- (2014) Kenny M. Hansson et al. BLOOD COAGULATION & FIBRINOLYSIS
- Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
- (2014) M. Levi et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
- (2014) Jack E. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversal Agents in Development for the New Oral Anticoagulants
- (2014) James Costin et al. POSTGRADUATE MEDICINE
- Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro
- (2014) Elisabeth Perzborn et al. THROMBOSIS RESEARCH
- LC–MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column
- (2014) Janice Pursley et al. Bioanalysis
- Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
- (2013) Xiaoli Wang et al. American Journal of Cardiovascular Drugs
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
- (2013) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tissue Factor-Mediated Activation of the Prothrombin Complex Concentrate (PCC) is Differently Inhibited by Dabigatran, Rivaroxaban, and Apixaban
- (2013) Nasiredin Sadeghi et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis
- (2013) Anne-Céline Martin et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- In vitroassessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban
- (2013) J. Dinkelaar et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood
- (2013) Gines Escolar et al. PLoS One
- Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
- (2013) Christian Chatelain et al. THROMBOSIS AND HAEMOSTASIS
- Direct Thrombin Inhibitors—A Case Indicating Benefit From ‘Plasmapheresis’ in Toxicity
- (2012) Jasmine Kamboj et al. AMERICAN JOURNAL OF THERAPEUTICS
- Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
- (2012) Raphael Marlu et al. THROMBOSIS AND HAEMOSTASIS
- Heparin-induced effects of prothrombin complex concentrates in thromboelastometry
- (2012) Gisela Scharbert et al. WIENER KLINISCHE WOCHENSCHRIFT
- Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
- (2011) Elise S. Eerenberg et al. CIRCULATION
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
- (2010) Zhaoqing Wang et al. THROMBOSIS AND HAEMOSTASIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started